Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure (DAPA-HF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03036124
Recruitment Status : Completed
First Posted : January 30, 2017
Last Update Posted : August 15, 2019
Sponsor:
Information provided by (Responsible Party):
AstraZeneca